Explore the words cloud of the CRC-MTOs project. It provides you a very rough idea of what is the project "CRC-MTOs" about.
The following table provides information about the project.
Coordinator |
FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
Organization address contact info |
Coordinator Country | Spain [ES] |
Total cost | 149˙955 € |
EC max contribution | 149˙955 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2018-PoC |
Funding Scheme | ERC-POC |
Starting year | 2018 |
Duration (year-month-day) | from 2018-12-01 to 2020-05-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) | ES (BARCELONA) | coordinator | 149˙955.00 |
Colorectal cancer (CRC) is one of the leading causes of death by cancer, which is largely associated to metastatic spread of the disease. Progress to develop efficient therapies, including immunotherapies, for patients with metastatic CRC has been hampered by the lack of preclinical models to study late stage CRC in an immunocompetent background. We have developed the first genetic mouse model of advanced CRC in immunocompetent mice. This model is based in a biobank of mouse tumor organoids (MTOs) derived from tumors arising in compound mice bearing genetic alterations in 4 driver genes associated to CRC progression: WNT, EGFR, p53, and TGF-beta signaling. We have demonstrated that these MTOs represent an invaluable tool for basic and pre-clinical research in CRC, in particular to test immunotherapies (Tauriello et al., Nature 2018).
Despite its potential, the MTO biobank has limitations for translational research. They were generated as academic tools which has prevented their use in technology transfer projects and collaborations with pharmaceutical companies. In addition, they do not cover all the different CRC subtypes. We propose to create an improved and more complete second-generation MTO biobank that a) recreates the described pre-clinical model of advanced CRC, b) extends the model collection to other subsets of CRCs by means of genome editing tools and c) grants freedom to operate. These newly generated MTOs will represent unique tools ready to be licenced and exploited in strategic public-private collaborations with the final goal to aid in the development of new drugs to treat advanced CRC patients.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CRC-MTOS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CRC-MTOS" are provided by the European Opendata Portal: CORDIS opendata.